Study of verapamil with antibiotics for drug-resistant bacteria in cancer patients
Treatments studied
Part of Cancer, Infections clinical trials.
This trial is testing whether adding verapamil (a common blood pressure medicine) to standard antibiotics can help kill bacteria that are resistant to many drugs. The bacteria are taken from cancer patients to see if this combination works better against the hard-to-treat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a cancer patient with a bacterial infection that is resistant to many antibiotics
- The bacteria must be from a clinical sample (like blood, urine, or wound) that is tested in a lab
- The bacteria must be classified as MDR (resistant to 3 or more types of antibiotics), XDR (resistant to all but 2 types), or PDR (resistant to all types)
- You are not participating if the bacteria is from a non-cancer patient, is a contaminant, is a duplicate, or is not resistant enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
This study tests two different pairs of strong antibiotics to see which works better at clearing hard-to-treat bacterial infections that don't respond to standard drugs. You would receive one of these two combinations and be monitored for how well it works and any side effects.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Antibiotic Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.